A brief review on the use of antidepressants in palliative care: Table 1

Rhondali, Wadih; Reich, M.; Filbet, Marilène

doi:10.1136/ejhpharm-2011-000024

Cited by 7 publications

(5 citation statements)

References 22 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Shuster et al (1999), many patients and physicians do not understand that psychiatric illness at the end of life can respond to treatment. This is despite the fact that good evidence now exists that antidepressants are an effective treatment of depression in the palliative care population (Rayner et al, 2011; Rhondali et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Psychiatry trainees’ views and educational needs regarding the care of patients with a life-limiting illness

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Psychiatry trainees’ views and educational needs regarding the care of patients with a life-limiting illness

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For instance, the British National Formulary (12) suggests prescribing mirtazapine to patients with sleep disturbance in depression (chapter 4.1.1). It is also possible mirtazapine is preferentially prescribed to treat depression in patients on the palliative care pathway (13)(14)(15)(16). Studies need to account for the possibility of such confounding.…”

Section: F Study Backgroundmentioning

confidence: 99%

PROTOCOL: A cohort study examining the association between mirtazapine and mortality risk in adults with a diagnosis of depression

Joseph¹,

Jack²,

Morriss

et al. 2021

Preprint

View full text Add to dashboard Cite

This protocol describes a cohort study comparing the risks of mortality and serious self-harm (suicide or near-fatal deliberate self-harm) between adults with depression prescribed mirtazapine, a selective serotonin reuptake inhibitor (SSRI), amitriptyline, or venlafaxine. The study is set within English primary care electronic health records from the Clinical Practice Research Datalink (CPRD) and covers the period 01 January 2005 - 30 November 2018. The study described uses an active comparator new user design: patients are included if they are first prescribed an SSRI before being prescribed mirtazapine, a different SSRI, amitriptyline, or venlafaxine as their second antidepressant. Patients are followed from the initial prescription for the second antidepressant until an outcome (mortality, serious self-harm), end of CPRD follow-up, or study end. Inverse probability of treatment weighting is used to account for confounding variables. The protocol was submitted to the CPRD Independent Scientific Advisory Committee for review and was approved in November 2019 (protocol number 19_241).

show abstract

“…In a palliative care or oncology setting, the frequency of major depression was 21 %; however, 40 % of patients may have some form of mood disorder (Mitchell et al 2011 ). The different classes of antidepressants used in palliative care have been recently reviewed (Rhondali et al 2012 ).…”

Section: Antidepressantsmentioning

confidence: 99%